Coxsackievirus Infections

A heterogeneous group of infections produced by coxsackieviruses, including HERPANGINA, aseptic meningitis (MENINGITIS, ASEPTIC), a common-cold-like syndrome, a non-paralytic poliomyelitis-like syndrome, epidemic pleurodynia (PLEURODYNIA, EPIDEMIC) and a serious MYOCARDITIS.

Also Known As:

Networked: 100 relevant articles (0 outcomes, 6 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Myocarditis (Carditis)
2.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
3.	Infections
4.	Type 1 Diabetes Mellitus (Autoimmune Diabetes)
5.	Human Influenza (Influenza)

Experts

1.	Luo, Honglin: 7 articles (09/2017 - 08/2003)
2.	Flodström-Tullberg, Malin: 5 articles (01/2020 - 02/2005)
3.	Zhang, Jingchun: 5 articles (01/2017 - 08/2003)
4.	Wong, Jerry: 4 articles (09/2017 - 07/2008)
5.	Fung, Gabriel: 3 articles (09/2017 - 10/2015)
6.	Lind, Katharina: 3 articles (12/2016 - 05/2010)
7.	Lowenstein, Charles J: 3 articles (03/2007 - 08/2004)
8.	Deng, Haoyu: 2 articles (01/2017 - 10/2015)
9.	Wang, Chen: 2 articles (01/2017 - 10/2015)
10.	Hühn, Michael H: 2 articles (12/2016 - 05/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Coxsackievirus Infections:

1.	Antiviral Agents (Antivirals)IBA 08/01/2023 - "As of yet, no antiviral drug has been authorized for the treatment of coxsackievirus infection. " 01/01/2022 - "Until date, no antiviral agent has been licensed for the treatment of Coxsackievirus infection. " 04/01/1977 - "The findings indicate that Coxsackievirus infection results in surface membrane alterations, but no evidence was obtained that antiviral antibody could react with the infected cells." 01/01/1974 - "Antiviral activity of N-phenyl-N'-aryl- or alkylthiourea derivatives in Coxsackie virus infections in mice." 10/11/2011 - "This review addresses antiviral therapeutics for cardiac coxsackievirus infections discovered over the last 25 years. "
2.	Proteins (Proteins, Gene)FDA Link 01/01/2008 - "Like poliovirus, coxsackievirus gene expression is controlled largely at the translation level and coxsackievirus infection results in profound changes in the profile of mRNAs with access to the protein synthesis machinery of the host cell. " 04/15/2004 - "To our knowledge, CAR-Fc is the only protein that has been shown to block coxsackievirus infection of the pancreas. " 07/09/2008 - "Coxsackievirus infection promotes protein ubiquitination, contributing to effective viral replication, probably through ubiquitin modification of viral polymerase." 08/01/2003 - "We have previously shown that coxsackievirus infection facilitates the ubiquitin/proteasome processing of the cell-cycle protein cyclin D1 and the tumor suppressor p53, which raises the possibility that the ubiquitin/proteasome pathway may be used by virus to promote viral replication. " 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
3.	adenovirus receptorIBA 05/01/2019 - "CEACAM-1 promotes myocardial injury following coxsackievirus infection by regulating the coxsackievirus-adenovirus receptor." 10/01/2017 - "Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor." 04/30/2004 - "Alternatively spliced soluble coxsackie-adenovirus receptors inhibit coxsackievirus infection." 08/29/2014 - "This study demonstrates that hiPSC-CMs express the coxsackievirus and adenovirus receptor, are susceptible to coxsackievirus infection, and can be used to predict antiviral drug efficacy. "
4.	UbiquitinIBA 09/01/2014 - "Taken together, the findings in this study suggest a novel mechanism through which coxsackievirus infection induces increased accumulation of ubiquitin conjugates and subsequent viral damage. " 09/01/2014 - "Coxsackievirus infection induces an abnormal accumulation of ubiquitin aggregates that are generally believed to be noxious to the cells and have a key role in viral pathogenesis. " 07/09/2008 - "Coxsackievirus infection promotes protein ubiquitination, contributing to effective viral replication, probably through ubiquitin modification of viral polymerase." 08/01/2003 - "We have previously shown that coxsackievirus infection facilitates the ubiquitin/proteasome processing of the cell-cycle protein cyclin D1 and the tumor suppressor p53, which raises the possibility that the ubiquitin/proteasome pathway may be used by virus to promote viral replication. "
5.	Peptide Hydrolases (Proteases)FDA Link 01/01/2017 - "Cleavage of Grb2-Associated Binding Protein 2 by Viral Proteinase 2A during Coxsackievirus Infection." 12/12/2006 - "We now show that during Coxsackievirus infection, the viral protease 3C(pro) cleaves inhibitor of kappaBalpha (IkappaBalpha). " 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
6.	Proteasome Endopeptidase Complex (Proteasome)IBA 08/01/2003 - "We have previously shown that coxsackievirus infection facilitates the ubiquitin/proteasome processing of the cell-cycle protein cyclin D1 and the tumor suppressor p53, which raises the possibility that the ubiquitin/proteasome pathway may be used by virus to promote viral replication. " 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
7.	Interferon LambdaIBA 09/01/2014 - "Our studies suggest that human hepatocytes express type III IFNs in response to a Coxsackievirus infection and highlight a novel role for type III IFNs in regulating hepatocyte permissiveness to this clinically relevant type of virus. " 09/01/2014 - "Moreover, whether or not type III IFNs protects hepatocytes from a Coxsackievirus infection has not been addressed. " 09/01/2014 - "Whether type III IFNs are produced by hepatocytes during a Coxsackievirus infection remains unknown. " 07/01/2013 - "Our novel observations suggest that type III IFNs may regulate viral replication and thereby contribute to reduced tissue damage and promote islet cell survival during coxsackievirus infection."
8.	Serine (L-Serine)FDA Link 01/03/2011 - "The present study explores the role of tripeptidyl peptidase II (TPPII), a serine peptidase contributing to protein turnover by acting downstream of the proteasome, in regulating coxsackievirus infection. "
9.	SeleniumIBA 01/01/2000 - "In studies of coxsackievirus infection and selenium deficiency in mice, we found that mice fed a selenium-deficient diet developed myocarditis, but mice fed a diet adequate in selenium did not. "
10.	DysferlinIBA 10/01/2015 - "Using both naturally occurring and genetically engineered dysferlin-deficient mice, we demonstrated that loss of dysferlin confers increased susceptibility to coxsackievirus infection and myocardial damage. " 10/01/2015 - "Our results in this study not only identify dysferlin deficiency as a novel host risk factor for viral myocarditis but also reveal a key mechanism by which coxsackievirus infection impairs cardiac function, leading to the development of dilated cardiomyopathy. "

Therapies and Procedures

1.	Therapeutics 10/11/2011 - "This review addresses antiviral therapeutics for cardiac coxsackievirus infections discovered over the last 25 years. " 10/11/2011 - "Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections." 12/07/2004 - "Interferons (IFNs)-alpha and -beta perform a fundamental role in innate and adaptive antiviral responses, thereby presenting as candidate therapeutics for coxsackievirus infections. " 01/01/1993 - "These results indicate that cytokines may serve as prognostic markers in the therapy of infectious diseases and also that WIN 54954 and LS 2616 are both possible candidates for treatment of coxsackievirus infections in man. "
2.	Transplantation 01/01/2006 - "No evidence suggests relapse of Coxsackie virus infection 5 months after transplantation. "
3.	Lasers (Laser) 12/01/1995 - "We measured unloaded sarcomere shortening velocity (V0) with laser diffraction (HeNe, lambda = 623.8 nm) 7 days after coxsackievirus infection (M) (n = 7) and after infection + monoclonal antibodies to eliminate T cells (T) (n = 4) and in normals (N) (n = 8). "